{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:39:27Z","timestamp":1786117167835,"version":"build-2736575974"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shanghai Henlius Biotech, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cutaneous squamous cell carcinoma (CSCC) accounts for 20% of all cutaneous cancers. Systemic treatment options for advanced CSCC (aCSCC) include immunotherapy, chemotherapy, and epidermal growth factor receptor (EGFR)-targeted therapy, although their efficacy is limited. HLX07 is a novel anti-EGFR antibody that showed preliminary anti-cancer activity and tolerability in phase I studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of HLX07 in patients with aCSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This is a multicenter, open-label, two-part phase II study. In Part 1, patients with metastatic or locally aCSCC not amenable to surgery or curative radiotherapy received 1500\u2009mg (group A) or 1000\u2009mg (group B) HLX07 intravenously every 3\u2009weeks. In Part 2, patients received HLX07 at dose level determined with Part 1 results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The primary endpoint was objective response rate (ORR) assessed by an independent radiology review committee (IRRC). Secondary endpoints included other efficacy endpoints, safety, pharmacokinetics, immunogenicity, and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Here we focus on Part 1 data. As of April 30, 2024, 31 patients were enrolled (group A, 21; group B, 10). Most patients had metastatic disease (85.7%; 90.0%). Per IRRC assessments, ORR was 19.0% (95% confidence interval (CI), 5.5\u201341.9) for group A and 60.0% (26.2\u201387.8) for group B; median progression-free survival was 4.9 (95% CI, 1.4\u20136.5) and 7.9 (95% CI, 2.2\u201311.1)\u2009months, and median duration of response was 5.0 (95% CI, 2.9\u2013not evaluable (NE)) and 7.4 (95% CI, 2.8\u2013NE)\u2009months, respectively. Median overall survival was 11.8\u2009months (95% CI, 5.9\u2013NE) and not reached (95% CI, 2.2\u2013NE). Grade \u2a7e3 treatment-related adverse events (TRAEs) occurred in 8 (38.1%) and 3 (30.0%) patients, respectively. No TRAE leading to death or treatment discontinuation was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05238363.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261456684","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:56:23Z","timestamp":1785848183000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial"],"prefix":"10.1177","volume":"18","author":[{"given":"Changxing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China"},{"name":"Department of Dermatology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People\u2019s Hospital), Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, Baiyun District, Guangzhou, Guangdong 510000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rare Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-1848","authenticated-orcid":false,"given":"Zhengfu","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Oncology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-4566","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Immunotherapy Center, Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chengdu Integrated TCM &amp; Western Medicine Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Oncology, Tianjin Cancer Institute &amp; Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengsheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangmen Central Hospital, Jiangmen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Maoming People\u2019s Hospital, Maoming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Hu","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futang","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Yu","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2206348"},{"issue":"1","key":"e_1_3_4_3_2","article-title":"The global, regional, national burden of cutaneous squamous cell carcinoma (1990\u20132019) and predictions to 2035","volume":"2023","author":"Guo A","year":"2023","unstructured":"Guo A, Liu X, Li H, et al. The global, regional, national burden of cutaneous squamous cell carcinoma (1990\u20132019) and predictions to 2035. Eur J Cancer Care 2023; 2023(1): 5484597.","journal-title":"Eur J Cancer Care"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101800"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1989.01410010125024"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1169"},{"key":"e_1_3_4_7_2","article-title":"Squamous cell skin cancer, NCCN guidelines version 1.2024","author":"National Comprehensive Cancer Network","year":"2024","unstructured":"National Comprehensive Cancer Network. Squamous cell skin cancer, NCCN guidelines version 1.2024. NCCN Clinical Practice Guidelines in Oncology, 2024.","journal-title":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"e_1_3_4_8_2","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-update 2023","volume":"193","author":"Stratigos AJ","year":"2023","unstructured":"Stratigos AJ, Garbe C, Dessinioti C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-update 2023. Eur J Cancer 2023; 193: 113252.","journal-title":"Eur J Cancer"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000799"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.364"},{"key":"e_1_3_4_11_2","unstructured":"United States Food and Drug Administration. FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma (accessed 14 December 2024)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00844-z"},{"key":"e_1_3_4_13_2","article-title":"Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol","volume":"39","author":"Verkerk K","year":"2024","unstructured":"Verkerk K, Geurts BS, Zeverijn LJ, et al. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol. Lancet Reg Health Eur 2024; 39: 100875.","journal-title":"Lancet Reg Health Eur"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14936"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu368"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000003"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123180"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16465"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14978"},{"key":"e_1_3_4_21_2","unstructured":"Highlights of Prescribing Information. ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company. ERBITUX\u00ae (cetuximab) injection for intravenous use https:\/\/pi.lilly.com\/us\/erbitux-uspi.pdf (accessed 14 December 2024)."},{"key":"e_1_3_4_22_2","unstructured":"Amgen Inc. VECTIBIX\u00ae (panitumumab) injection for intravenous use. Highlights of prescribing information https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/vectibix\/vectibix_pi.pdf (accessed 14 December 2024)."},{"key":"e_1_3_4_23_2","article-title":"Efficacy and toxicity of HLX07 as a new anti-EGFR monoclonal antibody for epithelial cancers","volume":"35","author":"Liu HE","year":"2017","unstructured":"Liu HE, Tseng C-L, Liu S, et al. Efficacy and toxicity of HLX07 as a new anti-EGFR monoclonal antibody for epithelial cancers. J Clin Oncol 2017; 35(15_suppl): e14078.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1988072"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01099-1"},{"key":"e_1_3_4_26_2","article-title":"Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors","volume":"41","author":"Li Q","year":"2023","unstructured":"Li Q, Guo Y, Xue J, et al. Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors. J Clin Oncol 2023; 41(16_suppl): e15001.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.221"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.94.3.361"},{"key":"e_1_3_4_29_2","unstructured":"E9 Statistical Principles for Clinical Trials. The international council for harmonisation of technical requirements for pharmaceuticals for human use https:\/\/database.ich.org\/sites\/default\/files\/E9_Guideline.pdf (1998 accessed 12 April 2026)."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0204"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.008"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007637"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9520"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2221"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261456684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261456684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261456684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:18:59Z","timestamp":1786022339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261456684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["10.1177\/17588359261456684"],"URL":"https:\/\/doi.org\/10.1177\/17588359261456684","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261456684"}}